Patents Examined by George W Kosturko
  • Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders
    Patent number: 9375430
    Abstract: Disclosed are compounds, compositions and methods for treating metabolic diseases, including obesity and diabetes. Such compounds are represented by formula (I) as follows: wherein Y and Z are defined herein.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: June 28, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Margery Connelly, Christopher M. Flores, Mark J. Macielag
  • Modulators of androgen synthesis
    Patent number: 9375433
    Abstract: The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: June 28, 2016
    Assignee: Tangent Reprofiling Limited
    Inventors: Suzanne Dilly, Gregory Stoloff, Paul Taylor
  • Formulations of 6-mercaptopurine
    Patent number: 9375403
    Abstract: The present invention provides improved formulations of 6-mercaptopurine that exhibit better bioavailability and faster dissolution than previous formulations.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: June 28, 2016
    Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD.
    Inventors: E. Itzhak Lerner, Moshe Flashner-Barak, Erwin v Achthoven, Hans Keegstra, Ruud Smit
  • Aziridine bisphenol ethers and related compounds and methods for their use
    Patent number: 9365510
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, R3, R4, M1, M2, X, L1, L2, J1, J2, a1, a2, b1 and b2 are as defined herein, and wherein at least one of M2 or L2 is a moiety comprising an aziridine, acrylamide or sulfonate functional group, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: June 14, 2016
    Assignees: British Columbia Cancer Agency Branch, The University of British Columbia
    Inventors: Raymond John Andersen, Marianne Dorothy Sadar
  • Matriptase inhibitors and uses thereof against orthomyxoviridae infections
    Patent number: 9365853
    Abstract: The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flu infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and preventing orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.
    Type: Grant
    Filed: May 28, 2012
    Date of Patent: June 14, 2016
    Inventors: Martin Richter, Richard Leduc, Eloic Colombo, Eric Marsault
  • Type II RAF kinase inhibitors
    Patent number: 9358231
    Abstract: The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: June 7, 2016
    Assignees: Dana-Farber Cancer Institute, Inc., University of Miami
    Inventors: Nathanael Gray, Hwan Geun Choi, Xianming Deng, Jianming Zhang, Izidore Lossos
  • Di-aspirin derivatives
    Patent number: 9351980
    Abstract: The invention relates to the use of di-aspirin (bis(2-carboxyphenyl)succinate) and its derivatives in the treatment of colon and colorectal cancer. It also relates to novel derivatives of di-aspirin and to a method of synthesis of the di-aspirin and its derivatives.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: May 31, 2016
    Assignee: The University of Wolverhampton
    Inventors: Christopher John Perry, Iain Douglas Nicholl
  • Acid salt forms of polymer-drug conjugates and alkoxylation methods
    Patent number: 9320808
    Abstract: Among other aspects, provided herein is a mixed-acid salt of a water-soluble polymer-drug conjugate, along with related methods of making and using the same. The mixed-salt acid salt is stably formed, and appears to be more resistant to hydrolytic degradation than the corresponding predominantly pure acid salt or free base forms of the polymer-drug conjugate. The mixed acid salt is reproducibly prepared and recovered, and provides surprising advantages over non-mixed acid salt forms of the water-soluble polymer drug conjugate.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: April 26, 2016
    Assignee: NEKTAR THERAPEUTICS
    Inventors: Anthony O. Chong, Seoju Lee, Bhalchandra V. Joshi, Brian Bray, Shaoyong Nie, Patrick L. Spence
  • Compositions and methods for inhibiting norovirus infection
    Patent number: 9321803
    Abstract: A composition for use in inhibiting the binding of a Norovirus to the histo-blood group antigen on the surface of epithelia is disclosed. The composition may contain a therapeutically effective amount of a binding-inhibiting compound and a carrier and/or excipient. The compounds may competitively bind a Norovirus that has the capability of binding with the histo-blood group antigens of secretor blood type, including A, B, AB, and O blood types. The compositions may be administered to a human prior to or after infection by a Norovirus, to prevent, ameliorate, or reduce the effects of an infection.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: April 26, 2016
    Assignee: Children's Hospital Medical Center
    Inventors: Xi Jiang, Ming Tan, Xufu Zhang
  • Kinase inhibitors for the treatment of cancer
    Patent number: 9308193
    Abstract: The present invention relates to kinase inhibitors for the treatment of cancer. Specifically, the present invention relates to the use of aminoactonitrile derivatives (AADs) in the treatment of cancer.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: April 12, 2016
    Assignee: PITNEY PHARMACEUTICALS PTY LIMITED
    Inventor: David Lawson Morris
  • Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
    Patent number: 9265749
    Abstract: Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: February 23, 2016
    Assignee: PATARA PHARMA, LLC
    Inventors: William Gerhart, Manfred Keller, Ahmet Tutuncu, Pravin Soni
  • Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
    Patent number: 9265768
    Abstract: The invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols, methods of preparing such compounds, compositions containing them and therapeutic use thereof.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: February 23, 2016
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Elisabetta Armani, Gabriele Amari, Carmelida Capaldi, Oriana Esposito, Ilaria Peretto
  • Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria
    Patent number: 9265744
    Abstract: Fulvic acid as the active ingredient is used in the treatment or inhibition of multi-drug resistant bacteria, in particular NDM-1 bacteria producing carbapenemase or extended-spectrum ?-lactamase (ES8L) resistant bacteria. The multi-drug resistant bacteria may be gram negative bacteria including, but not limited to, Klebsiella pneumoniae or Escherichia coli. The fulvic acid can be provided in combination with one or more antibiotics from the class of carbapenems or polymyxin antibiotics.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: February 23, 2016
    Assignee: NATRACINE UK LIMITED
    Inventors: Stephen William Leivers, Peter Warn
  • Modulation of phospholipase D for the treatment of neurodegenerative disorders
    Patent number: 9267122
    Abstract: The present invention relates to methods of treating neurodegenerative diseases comprising administering, to a subject in need of such treatment, one or more agent that inhibits or reduces the action, including the catalytic activity, of an enzyme of the phospholipase D family, such as phospholipase D1 and/or phospholipase D2. The present invention also relates to cell-based assays which may be used to identify agents that inhibit or reduce the activity of enzymes of the phospholipase D family and that may be used in the treatment of neurodegenerative diseases.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: February 23, 2016
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Gilbert DiPaolo, Tae-Wan Kim, Tiago Gil Oliveira
  • Silibinin component for the treatment of hepatitis
    Patent number: 9248115
    Abstract: The invention relates to the use of a silibinin component for the production of a medicament that is adapted for parenteral administration for the treatment of viral hepatitis, preferably of hepatitis B or C, in particular for the reduction of the virus load. The medicament preferably contains no silidianin and/or no silichristin and/or no isosilibinin.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: February 2, 2016
    Assignee: MADAUS GMBH
    Inventors: Lucio Claudio Rovati, Massimo Maria D'Amato, Ulrich Mengs, Ralf-Torsten Pohl, Peter Ferenci
  • Injectable bone void filler
    Patent number: 9248215
    Abstract: The present invention relates to a biodegradable fibrin based composition for injection into osseous defects or voids, which can be the result of osteoporosis, surgery, bone cysts, tumor removal or traumatic bone injury.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: February 2, 2016
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: John J. Barry, Andreas Goessl, Heinz Gulle, Monika Mangold, Melitta Bilban
  • Fluorescent antagonists of the A3 adenosine receptor
    Patent number: 9227979
    Abstract: Disclosed are compounds of the formula (I) which are fluorescently labeled antagonists of the A3 adenosine receptor: wherein A, R1, R2, and Y are as described herein. Also disclosed are diagnostic compositions and a method of diagnosis of a patient for a possible treatment by an antagonist of the A3 adenosine receptor, involving the use of one or more of these compounds as diagnostic agents.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: January 5, 2016
    Assignees: The United States of America, as represented by The Secretary, Department of Health and Human Services, Universita Degli Studi Di Trieste, Universita Degli Studi Di Padova
    Inventors: Kenneth A. Jacobson, Santhosh Kumar Thatikonda, Eszter Erika Kozma, Giampiero Spalluto, Stefano Moro, Stephanie Federico
  • Hydrocortisone nanotechnological delivery system
    Patent number: 9205093
    Abstract: A composition is provided having nano technological delivery of a medicament through the skin. The composition contains hydrocortisone, resveratrol and a sulfate free surfactant. The composition is formulated into a shampoo and the shampoo facilitates nano technological delivery of the hydrocortisone and the resveratrol through the skin of a user.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: December 8, 2015
    Inventor: Gary Marder
  • Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
    Patent number: 9205086
    Abstract: A pharmaceutical combination comprising an EGFR inhibitor and an Hsp90 inhibitor according to the following formulae (I) or (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof using pharmaceutical combinations disclosed herein.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: December 8, 2015
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Ronald K. Blackman, Kevin Paul Foley, David Proia
  • Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
    Patent number: 9199979
    Abstract: Thiazolylphenyl-benzenesulfonamido derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: December 1, 2015
    Assignee: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Maurizio Pulici, Gabriella Traquandi, Chiara Marchionni, Alessandra Scolaro, Nicoletta Colombo